Editor’s note: A recording of the conversation is embedded below.
Venture capital is notoriously opaque, and biotech is no exception. Which is why STAT’s Kate Sheridan dug deep into closely guarded returns data to try to figure out exactly which biotech-focused venture capitalists are actually doing well for their investors.
But that data is hard to find — and even then, it’s limited.
